TopoTarget Extravasation Drug Approved In EU; Not Yet In U.S.
By Jennifer Boggs
Friday, August 4, 2006
Danish company TopoTarget A/S reported European approval and a U.S. approvable letter for its first product, a drug designed to protect a cancer patient's tissue from the effects of anthracyclines upon accidental exposure during the administration of chemotherapy. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.